1. Torre, LA, Bray, F, Siegel, RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.
Google Scholar | Crossref | Medline | ISI2. Ferlay, J, Soerjomataram, I, Dikshit, R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–E386.
Google Scholar | Crossref | Medline | ISI3. Siegel, RL, Miller, KD, Jemal, A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34.
Google Scholar | Crossref | Medline4. Jones, PA, Baylin, SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–428.
Google Scholar | Crossref | Medline | ISI5. Sato, M, Shames, DS, Gazdar, AF, et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007; 2: 327–343.
Google Scholar | Crossref | Medline | ISI6. Herman, JG, Baylin, SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042–2054.
Google Scholar | Crossref | Medline | ISI7. Das, PM, Singal, R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632–4642.
Google Scholar | Crossref | Medline | ISI8. Merlo, A, Herman, JG, Mao, L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1: 686–692.
Google Scholar | Crossref | Medline | ISI9. Farag, AK, Roh, EJ. Death-associated protein kinase (DAPK) family modulators: current and future therapeutic outcomes. Med Res Rev 2019; 39: 349–385.
Google Scholar | Crossref | Medline10. Shiloh, R, Bialik, S, Kimchi, A. The DAPK family: a structure-function analysis. Apoptosis 2014; 19: 286–297.
Google Scholar | Crossref | Medline11. Kim, DH, Nelson, HH, Wiencke, JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer. Oncogene 2001; 20: 1765–1770.
Google Scholar | Crossref | Medline | ISI12. Liu, Y, Gao, W, Siegfried, JM, et al. Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer 2007; 7: 74.
Google Scholar | Crossref | Medline | ISI13. Buckingham, L, Penfield Faber, L, Kim, A, et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II non-small cell lung cancer patients. Int J Cancer 2010; 126: 1630–1639.
Google Scholar | Medline14. Lin, Q, Geng, J, Ma, K, et al. RASSF1A, APC, ESR1, ABCB1 and HOXC9, but not p16INK4A, DAPK1, PTEN and MT1G genes were frequently methylated in the stage I non-small cell lung cancer in China. J Cancer Res Clin Oncol 2009; 135: 1675–1684.
Google Scholar | Crossref | Medline15. Hoffmann, AC, Kaifi, JT, Vallböhmer, D, et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol 2009; 100: 414–417.
Google Scholar | Crossref | Medline16. Zhang, CY, Jin, YT, Xu, H, et al. Relationship between promoter methylation of p16, DAPK and RARB genes and the clinical data of non-small cell lung cancer. Chin J Med Genet 2011; 28: 23–28.
Google Scholar17. Jun, WU, Liang, B, Jianyou, HE, et al. Study on detection of aberrant promoter hypermethylation of p16 and DAP kinase in serum DNA from patients with non-small cell lung cancer. Chin J Lung Cancer 2002; 5: 188–190.
Google Scholar18. Li, Y, Fan, QX. The role of lung cancer related gene methylation in the early diagnosis of lung cancer. Chin J Oncol 2020; 42: 644–647.
Google Scholar19. Chan, EC, Lam, SY, Tsang, KW, et al. Aberrant promoter methylation in Chinese patients with non-small cell lung cancer: patterns in primary tumors and potential diagnostic application in bronchoalevolar lavage. Clin Cancer Res 2002; 8: 3741–3746.
Google Scholar | Medline20. Zöchbauer-Müller, S, Fong, KM, Virmani, AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249–255.
Google Scholar | Medline | ISI21. Jin, Y, Xu, H, Zhang, C, et al. Association of abnormal methylation of CpG islands in promoter domains of multiple tumor. Suppressor genes with non-small cell lung cancer. Chin J Clin Oncol 2010; 37: 1109–1114.
Google Scholar22. Kim, YT, Lee, SH, Sung, SW, et al. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection? Ann Thorac Surg 2005; 79: 1180–1188. Discussion 1180–1188.
Google Scholar | Crossref | Medline23. Ali, A, Kumar, S, Kakaria, VK, et al. Detection of promoter DNA methylation of APC, DAPK, and GSTP1 genes in tissue biopsy and matched serum of advanced-stage lung cancer patients. Cancer Invest 2017; 35: 423–430.
Google Scholar | Crossref | Medline24. Tang, X, Khuri, FR, Lee, JJ, et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1511–1516.
Google Scholar | Crossref | Medline25. Huang, X, Wu, C, Fu, Y, et al. Methylation analysis for multiple gene promoters in non-small cell lung cancers in high indoor air pollution region in China. Bull Cancer 2018; 105: 746–754.
Google Scholar | Crossref | Medline26. Ramirez, JL, Sarries, C, de Castro, PL, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett 2003; 193: 207–216.
Google Scholar | Crossref | Medline | ISI27. Safar, AM, Spencer, H, Su, X , et al. Methylation profiling of archived non-small cell lung cancer: a promising prognostic system. Clin Cancer Res 2005; 11: 4400–4405.
Google Scholar | Crossref | Medline28. Luo Jianglong, LK, Feng, X. Value of p16, DAPK and APC gene methylation in early diagnosis of lung cancer. JMinim Invasive Med2018; 13: 12–16.
Google Scholar29. Niklinska, W, Naumnik, W, Sulewska, A, et al. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC). Folia Histochem Cytobiol 2009; 47: 275–280.
Google Scholar | Crossref | Medline30. Guo, M, House, MG, Hooker, C, et al. Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res 2004; 10: 5131–5136.
Google Scholar | Crossref | Medline31. Yanagawa, N, Tamura, G, Oizumi, H, et al. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003; 94: 589–592.
Google Scholar | Crossref | Medline | ISI32. Ramirez, JL, Taron, M, Balaña, C, et al. Serum DNA as a tool for cancer patient management. Rocz Akad Med Bialymst (1995) 2003; 48: 34–41.
Google Scholar | Medline33. Lin, Q, Chen, L, Tang, Y, et al. The promoter hypermethylation of DAPK gene and p16 gene in sera from Chinese non-small cell lung cancer patients. Chin Ger J Clin Oncol 2006; 5: 184–188.
Google Scholar | Crossref34. Cao Li, SYCR, Zhang, Y, Wang, J, et al. Observation on the serum methylation status of RUNX3, RASSF1A, 3-OST-2, DAPK and PTPRO genes in patients with non-small cell lung cancer. Shandong Med J 2016; 56: 84–87.
Google Scholar35. Lin Qing, CLTY, Wang, J. Combined detection of serum DAPK gene and p16 gene methylation in patients with non-small cell lung cancer. Chin J Gerontol 2006; 26: 1304–1306.
Google Scholar36. Lu Degan, JX . Detection and significance of serum abnormal methylation of death associated protein kinase gene in patients with non-small cell lung cancer. Shandong Med J 2010; 50: 69–70.
Google Scholar37. Cuiying, WPZ . Methylation of RASSF1A, p16, DAPK and RUNX3 gene and its role in inner Mongolia non-small-cell lung cancer. J Inner Mongolia Med Univ 2016; 38: 89–102.
Google Scholar38. Yan Qi, ZY . Combined detection of CpG island methylation of 8 tumor suppressor gene promoters in serum [in Chinese]. Chin J Cancer Prev Treat 2018; 25: 8–10.
Google Scholar39. Peng, Z, Shan, C, Wang, H. Value of promoter methylation of RASSF 1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers. J Cent South Univ (Med Sci) 2010; 35: 247–253.
Google Scholar40. Hua, HR, Jin, KW, Ruan, YH, et al. Expression and aberrant methylation of DAPK gene of lung cancer tissues in Yunnan tin miners. Chin Occup Med 2007; 34: 87–90.
Google Scholar41. Toyooka, S, Toyooka, KO, Miyajima, K, et al. Epigenetic down-regulation of death-associated protein kinase in lung cancers. Clin Cancer Res 2003; 9: 3034–3041.
Google Scholar | Medline42. Russo, AL, Thiagalingam, A, Pan, H, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res 2005; 11: 2466–2470.
Google Scholar | Crossref | Medline | ISI43. Vallböhmer, D, Brabender, J, Yang, D, et al. DNA Methyltransferases messenger RNA expression and aberrant methylation of CpG islands in non-small-cell lung cancer: association and prognostic value. Clin Lung Cancer 2006; 8: 39–44.
Google Scholar | Crossref | Medline44. Yanagawa, N, Tamura, G, Oizumi, H, et al. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers. Lung Cancer 2007; 58: 131–138.
Google Scholar | Crossref | Medline45. Wang, Y, Zhang, D, Zheng, W, et al. Multiple gene methylation of non-small cell lung cancers evaluated with 3-dimensional microarray. Cancer 2008; 112: 1325–1336.
Google Scholar | Crossref | Medline | ISI46. Zhang, Y, Wang, R, Song, H, et al. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. Cancer Lett 2011; 303: 21–28.
Google Scholar | Crossref | Medline47. Kontic, M, Stojsic, J, Jovanovic, D, et al. Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma. Clin Lung Cancer 2012; 13: 297–303.
Google Scholar | Crossref | Medline48. Guo, M, Alumkal, J, Drachova, T, et al. CHFR Methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer. Discov Med 2015; 19: 151–158.
Google Scholar | Medline49. Belinsky, SA, Grimes, MJ, Casas, E, et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007; 96: 1278–1283.
Google Scholar | Crossref | Medline50. Fischer, JR, Ohnmacht, U, Rieger, N, et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine. Lung Cancer 2007; 56: 115–123.
Google Scholar | Crossref | Medline51. Fujiwara, K, Fujimoto, N, Tabata, M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. Clin Cancer Res 2005; 11: 1219–1225.
Google Scholar | Medline | ISI52. Divine, KK, Pulling, LC, Marron-Terada, PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers. Int J Cancer 2005; 114: 400–405.
Google Scholar |